--- title: "ANI Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 266.04 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295223722.md" datetime: "2026-08-07T11:02:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295223722.md) - [en](https://longbridge.com/en/news/295223722.md) - [zh-HK](https://longbridge.com/zh-HK/news/295223722.md) generator: "portal-rs" --- # ANI Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 266.04 M Revenue: As of FY2026 Q2, the actual value is USD 266.04 M, beating the estimate of USD 260.13 M. EPS: As of FY2026 Q2, the actual value is USD 1.05, missing the estimate of USD 1.11. EBIT: As of FY2026 Q2, the actual value is USD 40.73 M. ### Financial Performance Overview #### Total Net Revenues ANI Pharmaceuticals, Inc. reported total net revenues of $266.0 million for the second quarter of 2026, representing a 25.9% increase year-over-year from $211.4 million in Q2 2025. #### Operational Metrics - **Net Income:** GAAP net income available to common shareholders was $24.7 million for Q2 2026, compared to $8.1 million in the prior year period. - **Adjusted Non-GAAP EBITDA:** Adjusted Non-GAAP EBITDA reached $71.6 million in Q2 2026, an increase of 32.4% from $54.1 million in Q2 2025. - **Gross Margin:** GAAP gross margin decreased to 62.4% in Q2 2026 from 64.7% in the prior year, while non-GAAP gross margin decreased to 62.6% from 64.9%. - **Research and Development Expenses:** GAAP research and development expenses decreased -10.8% to $14.7 million, and non-GAAP research and development expenses decreased -11.4% to $14.1 million in Q2 2026. - **Selling, General, and Administrative Expenses:** GAAP selling, general, and administrative expenses increased 12.1% to $91.7 million, and non-GAAP selling, general, and administrative expenses increased 20.2% to $80.7 million in Q2 2026. - **Operating Income:** GAAP Operating income was $40.460 million in Q2 2026, compared to $13.892 million in the second quarter of 2025. #### Segment Revenue - **Rare Disease:** Total net revenues for the Rare Disease segment, including Cortrophin Gel and ILUVIEN, increased 30.7% to $135.8 million in Q2 2026. Rare Disease and Brands revenue for Q2 2026 was $165.4 million. - Purified Cortrophin® Gel net revenues were $117.1 million, an increase of 43.5% over the same period in 2025. - ILUVIEN® net revenues were $18.7 million, a decrease of -16.1% over the same period in 2025. - **Brands:** Brands net revenues were $11.8 million, a decrease of -10.5% over the same period in 2025. - **Brand Royalties and Other Revenues:** The company recognized $17.7 million, comprising $9.7 million of royalties on net sales of pitolisant-based products and $8.0 million for work completed toward development milestones under the Harmony Agreement. - **Generics:** Generics net revenues increased 9.7% to $99.1 million over the same period in 2025. Other generic revenues were $1.6 million, a decrease of -59.0%. Total Generics and Other net revenues were $100.6 million, an increase of 6.8% in Q2 2026. Generics and Other revenue for Q2 2026 was $100.7 million. - **Licensing Revenue:** An $8 million development milestone payment was recognized in Q2 2026, with the remaining $2 million expected in Q3 2026. #### Cash Flow and Liquidity - Cash flow from operations on a year-to-date basis was $115.0 million. - The company held $360.2 million in unrestricted cash and cash equivalents as of June 30, 2026. Cash was $360 million as of June 30, 2026. #### Other Key Metrics - **Net Leverage:** Net leverage was approximately 1.0x as of June 30, 2026, based on trailing twelve months adjusted Non-GAAP EBITDA of $260 million. - **Net Accounts Receivable:** Net accounts receivable totaled $274.5 million. - **Outstanding Debt:** The principal value of outstanding debt was $620.9 million. - **Product Launches:** ANI Pharmaceuticals, Inc. launched 12 new Generics products year-to-date and is on track for at least 15 new product launches in 2026. - **Share Repurchase Program:** The board of directors authorized a share repurchase program of up to $100.0 million in common stock through May 2029. ### Outlook / Guidance for Full Year 2026 ANI Pharmaceuticals, Inc. reaffirmed its full year 2026 total net revenue guidance of $1,080 million to $1,140 million and adjusted non-GAAP EBITDA guidance of $285 million to $300 million. The company expects full year adjusted non-GAAP gross margin between 59.9% and 60.9% and an annual U.S. GAAP effective tax rate between 26% and 28%. Cortrophin Gel net revenue guidance was adjusted to $520 million to $540 million, reflecting 50-55% growth for the full year. ### Related Stocks - [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md) ## Related News & Research - [Globeflex Capital L P Takes Position in ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/296757387.md) - [ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/295227182.md) - [Amentum-Laing O'Rourke JV wins ANI contract for Australia nuclear submarine shipyard program](https://longbridge.com/en/news/296228605.md) - [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md) - [The Stocks Hiding in AI’s “Magical Spaces”](https://longbridge.com/en/news/296132093.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**